Keywords: MannKind, Afrezza, Cephalon, Nuvigil, Jet lag, Inhaled insulin, USA, FDA, Diabetes

US marketing delay for MannKind’s Afrezza and Cephalon drops Nuvigil for jet lag

Article | 04 January 2011

Print This

The US Food and Drug Administration disappointed two US drugmakers last week as it announced that it needs more time ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in